[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![whispertickers Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1937935302200373248.png) WhisperTick [@whispertickers](/creator/twitter/whispertickers) on x XX followers
Created: 2025-07-10 13:50:39 UTC

Collegium Pharmaceutical's rise in the specialty pharma sector is worth attention. 🎯 $COLL is set for a XX% upside, with a target of $XXXXX. Here's a taste of how:

• Despite trading at a discount, COLL boasts strong cash flow and growth potential.
• The pain management market is £75 billion in size and growing at XXX% annually—ageing population and non-opioid solutions in play.
• Xtampza® ER and Jornay PM® lead their diversified portfolio, offering strategic advantages.
• The ongoing share repurchase program sweetens the deal.

Risky business? Of course, with opioid litigation and generic threats. But if COLL plays its cards right, the rewards could be substantial. Dive into more details here:

![](https://pbs.twimg.com/media/GvgDTj2XcAI-_JR.png)

XX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1943306877355335876/c:line.svg)

**Related Topics**
[cash flow](/topic/cash-flow)
[$coll](/topic/$coll)

[Post Link](https://x.com/whispertickers/status/1943306877355335876)